Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

J M Jürgensmeier; H-J Schmoll; J D Robertson; L Brooks; M Taboada; S R Morgan; D Wilson; P M Hoff

首页> 外文期刊>British Journal of Cancer >Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

【24h】

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

机译：VEGF，sVEGFR-2和CEA在西地那尼，贝伐单抗和化疗比较的mCRC研究中的预后和预测价值

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:The prognostic/predictive value of potential vascular endothelial growth factor (VEGF) signalling biomarkers was evaluated retrospectively using samples from two randomized Phase III studies (HORIZON II and III) investigating cediranib in metastatic colorectal cancer (mCRC).

机译：背景：使用两项西得乐单抗治疗转移性结直肠癌（mCRC）的两项随机III期研究（HORIZON II和III），回顾性评估了潜在的血管内皮生长因子（VEGF）信号生物标志物的预后/预测价值。

著录项

来源
《British Journal of Cancer》 |2013年第6期|共8页
作者
J M Jürgensmeier; H-J Schmoll; J D Robertson; L Brooks; M Taboada; S R Morgan; D Wilson; P M Hoff;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer [J] . PerroudH.A., RicoM.J., AlasinoC.M., Indian journal of cancer. . 2013,第2期

机译：晚期乳腺癌患者基线VEGF / sVEGFR-2和VEGF / TSP-1比率与使用环磷酰胺和塞来昔布对节律化疗的反应之间的关联
2. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease [J] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, BMC Medicine . 2012,第1期

机译：根据转移性疾病的扩展程度，KRAS基因型在接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的转移性结直肠癌（MCRC）患者中的预后价值
3. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON i study [J] . BarJ., SpencerS., MorganS., Clinical colorectal cancer . 2014,第1期

机译：化疗和贝伐单抗或西地尼布治疗的晚期大肠癌患者乳酸脱氢酶同工酶谱与预后的相关性：HORIZON i研究的回顾性分析
4. Prognostic Significance of COX-2 and VEGF in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy [C] . Gang-Ping WANG, Xue WANG, Zhao-Jun DING, International Conference on Biological Sciences and Technology . 2016

机译：Cox-2和VEGF在接受新辅助化疗的乳腺癌患者中的预后意义
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Prognostic and predictive value of VEGF sVEGFR-2 and CEA in mCRC studies comparing cediranib bevacizumab and chemotherapy [O] . J M Jürgensmeier, H-J Schmoll, J D Robertson, 2013

机译：VEGFsVEGFR-2和CEA在西地那尼贝伐单抗和化学疗法比较的mCRC研究中的预后和预测价值
7. Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT) [O] . T.W. Kim, Y.S. Park, K. Muro, 2017

机译：转移性结肠直肠癌二线化疗的随机，非劣等，III期试验（MCRC），比较Xeliri + Bevacizumab的疗效和安全性与Folfiri + Bevacizumab（Axept）

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅